Efficacy of Topical Finasteride 0.5% vs 17α-Estradiol 0.05% in the Treatment of Postmenopausal Female Pattern Hair Loss: A Retrospective, Single-Blind Study of 119 Patients

Efficacy of Topical Finasteride 0.5% vs 17α-Estradiol 0.05% in the Treatment of Postmenopausal Female Pattern Hair Loss: A Retrospective, Single-Blind Study of 119 Patients

Authors

  • Alfredo Rossi Division of Dermatology, Department of Internal Medicine and Medical Specialties, Sapienza University, Rome, Italy
  • Francesca Magri Division of Dermatology, Department of Internal Medicine and Medical Specialties, Sapienza University, Rome, Italy
  • Andrea D'Arino Division of Dermatology, Department of Internal Medicine and Medical Specialties, Sapienza University, Rome, Italy
  • Flavia Pigliacelli Division of Dermatology, Department of Internal Medicine and Medical Specialties, Sapienza University, Rome, Italy
  • Marta Muscianese Division of Dermatology, Department of Internal Medicine and Medical Specialties, Sapienza University, Rome, Italy
  • Pierpaolo Leoncini Department of Pediatric Hematology and Oncology, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Bambino Gesù Children's Hospital, Rome, Italy
  • Gemma Caro Division of Dermatology, Department of Internal Medicine and Medical Specialties, Sapienza University, Rome, Italy
  • Alessandro Federico Division of Dermatology, Department of Internal Medicine and Medical Specialties, Sapienza University, Rome, Italy
  • Maria Caterina Fortuna Division of Dermatology, Department of Internal Medicine and Medical Specialties, Sapienza University, Rome, Italy
  • Marta Carlesimo Division of Dermatology, Department of Internal Medicine and Medical Specialties, Sapienza University, Rome, Italy

Keywords:

female pattern hair loss, topical finasteride, 17 α–estriadol, minoxidil

Abstract

Background and Objectives: Female pattern hair loss (FPHL) is a common form of scalp hair loss that occurs in 38% of females. Currently, minoxidil solution is the only therapy approved by the US Food and Drug Administration, but many other treatments are used, including cyproterone acetate, spironolactone, topical 17α-estradiol, and prostaglandin analogs. Systemic finasteride has been considered a treatment option in women even though its teratogenic effects tend to limit its prescription. Recently, topical finasteride has been evaluated to limit the side effect profile of the drug. The objective of the present study is to compare retrospectively the efficacy of topical 0.05% 17α-estradiol solution and a 0.5% finasteride lotion in the treatment of FPHL.

Patients and Methods: We enrolled 119 postmenopausal female patients. The first group comprised 69 women treated with finasteride 0.5% and minoxidil 2%. The second group included 50 women treated with 17α-estradiol 0.05% and minoxidil 2%. At baseline and at 6- and 12- to 18-month follow-up, global photographs were systematically taken. Three operators blind to the prescribed treatment evaluated photographs using a 7-point scale. One-way analysis of variance and unpaired Student t tests were performed to analyze 7-point scale scores.

Results: The improvement was statistically significant from 6 months to 12-18 months, both for finasteride (P < 0.005) and 17α-estradiol (P < 0.05). The efficacy of topical finasteride was significantly greater than that of 17α-estradiol solution, both at the 6-month (P < 0.05) and at the 12- to 18-month follow-up (P < 0.005). In general, the highest improvement was observed after 12-18 months of treatment with topical finasteride therapy.

Conclusions: Topical finasteride 0.5% in combination with minoxidil 2% could represent a valid therapeutic option for the treatment of postmenopausal FPHL, showing higher efficacy than topical 17α-estradiol with minoxidil 2% both at 6-month and 12- to 18-month follow-up.

References

Birch MP, Messenger JF, Messenger AG. Hair density, hair diameter and the prevalence of female pattern hair loss. Br J Dermatol. 2001;144; 297-304.

https://doi.org/10.1046/j.1365-2133.2001.04018.x

PMid:11251562

Price VH. Androgenetic alopecia in women. J Investig Dermatol Symp Proc. 2003;8; 24-27.

https://doi.org/10.1046/j.1523-1747.2003.12168.x

PMid:12894991

Olsen EA. Female pattern hair loss and its relationship to permanent/cicatricial alopecia: a new perspective. J Investig Dermatol Symp Proc. 2005;10; 217-221.

https://doi.org/10.1111/j.1087-0024.2005.10109.x

PMid:16382668

Messenger AG. Hair through the female life cycle. Br J Dermatol. 2011;165 Suppl 3; 2-6.

https://doi.org/10.1111/j.1365-2133.2011.10628.x

PMid:22171678

Cousen P, Messenger A. Female pattern hair loss in complete androgen insensitivity syndrome. Br J Dermatol. 2010;162; 1135-1137.

https://doi.org/10.1111/j.1365-2133.2010.09661.x

PMid:20128792

Rossi A, Anzalone A, Fortuna MC, Caro G, Garelli V, Pranteda G, et al. Multi-therapies in androgenetic alopecia: review and clinical experiences. Dermatol Ther. 2016;29; 424-432.

https://doi.org/10.1111/dth.12390

PMid:27424565

Iorizzo M, Vincenzi C, Voudouris S, Piraccini BM, Tosti A. Finasteride treatment of female pattern hair loss. Arch Dermatol. 2006;142; 298-302.

https://doi.org/10.1001/archderm.142.3.298

PMid:16549704

Olszewska M, Rudnicka L. Effective treatment of female androgenic alopecia with dutasteride. J Drugs Dermatol. 2005;4; 637-640.

Lee SW, Juhasz M, Mobasher P, Ekelem C, Mesinkovska NA. A Systematic Review of Topical Finasteride in the Treatment of Androgenetic Alopecia in Men and Women. J Drugs Dermatol. 2018;17; 457-463.

Choe SJ, Lee S, Choi J, Lee WS. Therapeutic Efficacy of a Combination Therapy of Topical 17alpha-Estradiol and Topical Minoxidil on Female Pattern Hair Loss: A Noncomparative, Retrospective Evaluation. Ann Dermatol. 2017;29; 276-282.

https://doi.org/10.5021/ad.2017.29.3.276

PMid:28566902 PMCid:PMC5438932

Moos WH, Dykens JA, Howell N. 17α-estradiol: a less-feminizing estrogen. Drug Development Research. 2008;69; 177-184.

https://doi.org/10.1002/ddr.20244

Rossi A, Iorio A, Scarnò M, Fortuna MC, Priolo L, Di Nunno D, et al. Use of Topical Minoxidil, 17α-Estradiol and Hydrocortisone Butyrate in Frontal Fibrosing Alopecia. European Journal of Inflammation. 2014;12; 399-404.

https://doi.org/10.1177/1721727X1401200219

Whiting DA. Diagnostic and predictive value of horizontal sections of scalp biopsy specimens in male pattern androgenetic alopecia. J Am Acad Dermatol. 1993;28; 755-763.

https://doi.org/10.1016/0190-9622(93)70106-4

Alfredo R, Carmen C, Luca M, Alessandra I, Elisabetta S, Stefano C. Minoxidil Use in Dermatology, Side Effects and Recent Patents. Recent Patents on Inflammation & Allergy Drug Discovery. 2012;6; 130-136.

https://doi.org/10.2174/187221312800166859

PMid:22409453

Walsh DS, Dunn CL, James WD. Improvement in androgenetic alopecia (stage V) using topical minoxidil in a retinoid vehicle and oral finasteride. Arch Dermatol. 1995;131; 1373-1375.

https://doi.org/10.1001/archderm.131.12.1373

PMid:7492124

Buhl AE, Waldon DJ, Conrad SJ, Mulholland MJ, Shull KL, Kubicek MF, et al. Potassium channel conductance: a mechanism affecting hair growth both in vitro and in vivo. J Invest Dermatol. 1992;98; 315-319.

https://doi.org/10.1111/1523-1747.ep12499788

PMid:1545141

Rogers NE, Avram MR. Medical treatments for male and female pattern hair loss. J Am Acad Dermatol. 2008;59; 547-566; quiz 567-548.

https://doi.org/10.1016/j.jaad.2008.07.001

PMid:18793935

Fabbrocini G, Cantelli M, Masara A, Annunziata MC, Marasca C, Cacciapuoti S. Female pattern hair loss: A clinical, pathophysiologic, and therapeutic review. Int J Womens Dermatol. 2018;4; 203-211.

https://doi.org/10.1016/j.ijwd.2018.05.001

PMid:30627618 PMCid:PMC6322157

Hu AC, Chapman LW, Mesinkovska NA. The efficacy and use of finasteride in women: a systematic review. Int J Dermatol. 2019.

https://doi.org/10.1111/ijd.14370

PMid:30604525

Suchonwanit P, Iamsumang W, Rojhirunsakool S. Efficacy of Topical Combination of 0.25% Finasteride and 3% Minoxidil Versus 3% Minoxidil Solution in Female Pattern Hair Loss: A Randomized, Double-Blind, Controlled Study. Am J Clin Dermatol. 2019;20; 147-153.

https://doi.org/10.1007/s40257-018-0387-0

PMid:30206824

Kim JH, Lee SY, Lee HJ, Yoon NY, Lee WS. The Efficacy and Safety of 17alpha-Estradiol (Ell-Cranell(R) alpha 0.025%) Solution on Female Pattern Hair Loss: Single Center, Open-Label, Non-Comparative, Phase IV Study. Ann Dermatol. 2012;24; 295-305.

https://doi.org/10.5021/ad.2012.24.3.295

PMid:22879713 PMCid:PMC3412238

Caserini M, Radicioni M, Leuratti C, Annoni O, Palmieri R. A novel finasteride 0.25% topical solution for androgenetic alopecia: pharmacokinetics and effects on plasma androgen levels in healthy male volunteers. Int J Clin Pharmacol Ther. 2014;52; 842-849.

https://doi.org/10.5414/CP202119

PMid:25074865

Downloads

Published

2020-04-20

Issue

Section

Research

How to Cite

1.
Efficacy of Topical Finasteride 0.5% vs 17α-Estradiol 0.05% in the Treatment of Postmenopausal Female Pattern Hair Loss: A Retrospective, Single-Blind Study of 119 Patients. Dermatol Pract Concept [Internet]. 2020 Apr. 20 [cited 2024 Jul. 13];10(2):e2020039. Available from: https://dpcj.org/index.php/dpc/article/view/dermatol-pract-concept-articleid-dp1002a39

Share